Speakers

Catherine ABI-HABIB

Partner
McKinsey

Hani ABOUHALKA

Company Group Chairman
Johnson & Johnson Medical Devices Companies Europe, Middle East & Africa (EMEA)

Greg AHLBERG

Senior Vice President
Abbott Core Diagnostics

Bassil AKRA

CEO
QUNIQUE GmbH

Ali M AL-DALAAN

Chair GHWP/Vice Executive President
Medical Devices Sector, SFDA

Bjorn ALBRECHT

Partner
McKinsey

Charles ALESSI

Chief Clinical Officer
HIMSS

Anna Eva AMPELAS

Head of Unit / Directorate General for Health and Food Safety
European Commission / Medical Devices, Health Technology Assessment (SANTE.DDG1.B.6)

Lieven ANNEMANS

Professor of Health Economics
Vrije Universiteit Brussel and Ghent University

Ingrid BAELE

Director IP Advisory
Deloitte

Paulinka BANDEL

Head of Content & System Marketing
Dräger Schweiz AG

Birgit BAUER

Patient expert

Thierry BERNARD

CEO
Qiagen

Serge BERNASCONI

CEO
MedTech Europe

Odile BIGAIGNON

VP Sleep & Respiratory Care Marketing, EMEA
ResMed

Peter BLENKINSOP

International Pharmaceutical & Medical Device
Privacy Consortium (IPMPC)

Mark BLOEMENDAAL

CEO
Angiogenesis Analytics

Patrick BOISSEAU

Director General, Strategic Initiatives
MedTech Europe

Jaap BONJER

Amsterdam University Medical Centre

Gerhard BOTHMA

Global Director Health Economics and Governmental Affairs
Molnlycke Health Care

Juliet BOUVERIE

CEO
Stroke Association

Natale BOVA

Chair of IVD Regulatory Forum at Confindustria Dispositivi Medici, the Italian Association of Medical Device Industry
Quality Assurance & Regulatory Affairs Director, Instrumentation Laboratory S.p.A. - a Werfen Company

Ralph BREUER

Partner
McKinsey

Mary Devlin CAPIZZI

Partner
Faegre Drinker Biddle & Reath

Alexandre CECCALDI

Coordinator of the H2020 NOBEL project
General secretary of the European Technology Platform on Nanomedicine (ETPN)

Karin CERRI

Head Health Economics & Market Access Medical Devices Europe, Middle East & Africa
Johnson & Johnson

Richard CHARTER

Vice President of MedTech Market Access
Alira Health

Salah-Dine CHIBOUT

Global Investigative Safety
Novartis

Bernard COLOMBO

Board member, MedTech Europe
President Europe Middle East, Africa and Latin America, Roche Diagnostics International

Erica CONWAY

Global Head
IVD Medical Devices, Regulatory Services, BSI

Remi CORLIN

CEO
Hemeo

Gwenole COZIGOU

Director, Sustainable Industry and Mobility (GROW.DDG1.C), Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs
European Commission

Karl D'SOUZA

Director - Life Sciences Industry Solution
Dassault Systemes

Ingmar DE GOOIJER

Healthcare industry observer

Michel DE RIDDER

Partner Regulatory compliance
Deloitte Belgium

Brigitte DE VET

Vice President
Materialise Medical

Pierre DELSAUX

Deputy Director-General, DG SANTE
European Commission

Céline DESWARTE

EU Data Protection Officer
Boston Scientific

Emmet DEVEREUX

Director, Government and Regulatory Affairs
Cook Medical EMEA Group Limited

Mick FARRELL

CEO
ResMed

Mary FAULKNER

Program Manager
IQVIA

Larry FERRERE

Senior Director Integrated Compliance and Technology Solutions
IQVIA

Pat FOGARTY

Vice President, Assistant General Counsel, and Director, Civil Justice Policy
AdvaMed

Alex FORREST

Head of Life Sciences
Chubb

Cristiano FRANZI

Senior Vice President and President EMEA
Baxter

Morten FROST

Senior Vice President & General Manager
Veracyte

Paul GARASSUS

President
European Union of Private Hospitals (UEHP)

Miquel-Àngel GARCIA

Managing Director
Olympus Europa SE & Co. KG

Götz GERECKE

Managing Director & Senior Partner
Boston Consulting Group (BCG)

Jamie GRAMZ

Head of Digital Applications and Global Marketing
Siemens Healthineers

Axel GRIEWEL

Associate Director
BCG Platinion

Trevor GUNN

Vice President International Relations , Medtronic
Chair, International Affairs Committee, MedTech Europe

Iñaki GUTIERREZ IBARLUZEA

President of the Board of Directors - HTAi
Director of Organisational and Managerial Innovation - Basque Foundation for Health Innovation and Research (BIOEF)

Anna HALLERSTEN

Director - Head Regulatory Policy Europe
Roche Diagnostics International Ltd.

Erik HANSSON

Deputy Head of Unit
DG SANTE, European Commission

Joe HARRISON

Chief Executive Officer
Milton Keynes University Hospital, UK

Meike HAUSMANN

Department Manager, HCP/O Consulting Management, Medical Systems Division
OLYMPUS EUROPA SE & CO. KG

Kenny HENDERSON

Partner
CMS

Claudia HERBEN

Vice President Strategic Solutions Medical Devices EMEA
Johnson & Johnson

Sabina HOEKSTRA-VAN DEN BOSCH

Regulatory Strategy Principal TÜV Süd / Chair NB-Med Executive Committee / Vice-President Team-NB

Ffion JACKSON

Head of Laboratory Diagnostics Product-Related Environmental Protection & EHS Regulatory Standards
Siemens Healthineers

Mirgen JAKU

EMEA Lead Digital Surgery
Ethicon

Timothy JINKS

Head of Drug Resistant Infections Programme
Wellcome Trust

Phil JOHNSON

Senior Principal
IQVIA Quality Compliance Solutions

Scott KENNEDY

Senior Adviser and Trustee Chair in Chinese Business & Economics
CSIS | Center for Strategic & International Studies

Regina KLOSS-WOLF

Director Market Access & Strategic Alliances Core Diagnostics Europe, Africa, Middle East, Turkey & Russia
Abbott

Lorenz KODDERITZSCH

Vice President Law, Consumer Medical Devices EMEA
Johnson & Johnson

Xenofon KONTARGYRIS

Data Protection Manager, Data Protection, Corporate Governance
OLYMPUS EUROPA SE & CO. KG

Ewald KREID

Zimmer Biomet

Jean-Luc LEMERCIER

Corporate Vice President, EMEA Canada & Latin America
Edwards Lifesciences

Jill LOCKETT

Managing Director
Kings Health Partners

Elizabeth MACINTYRE

MD PhD FRCP FRCPath, Vice-Présidente, Stratégie Internationale, Université de Paris, Onco-hématologie biologique and INSERM UMR1151, INEM
Board Member, BioMed Alliance - President-Elect, European Hematology Association (EHA)

Jean-David MALO

Director
European Innovation Council

Hans MARTENS

Senior Advisor
European Policy Centre

David MATUSIEWICZ

Dean and Institute Director
FOM University

Amanda MAXWELL

MedTech Insight

Ashley MCEVOY

Executive Vice President, Worldwide Chairman, Medical Devices
Johnson & Johnson

Tamir MEIRI

Senior Manager, Venture Investments
Johnson & Johnson Innovation

Pierre MEULIEN

Executive Director
IMI2

Bert-Arjan MILLENAAR

Founder & CEO
NLC

Emilia MILOIU

Senior Manager Environment & Sustainability
MedTech Europe

Fadzai MUNYARADZI

Corporate Social Responsibility Manager Europe
Medline

Mike MUSSALLEM

Chairman and Chief Executive Officer
Edwards Lifesciences

Basir MUSTAGHNI

Managing Director & Partner
Boston Consulting Group (BCG)

Paul NEMITZ

Principal Adviser, DG Justice
European Commission

Cynthia O'DONOGHUE

Partner
ReedSmith

Megan OLSON

Global Chief Compliance Officer
Coloplast

Tomris OZBEN

President-Elect
European Federation of Clinical Chemistry and Laboratory Medicine

Andreas PÜRDE

Director Active Medical Devices
TÜV SÜD

Helen PARDOE

Chief Clinical Information Officer (C.C.I.O.), Consultant Colorectal Surgeon
The Princess Alexandra Hospitals NHS Trust

Terry PARLETT

Commercialisation Director
Cambridge Enterprise

Oliver PEARCE

Orthopaedic surgeon
Milton Keynes University Hospital, UK

Rosanna PEELING

Professor and Chair of Diagnostics Research and Director of the International Diagnostics Centre
London School of Hygiene & Tropical Medicine

Jean-Louis PEPIN

Pulmonologist
Grenoble Alpes University Hospital

Wolfgang PHILIPP

Head of Unit, Directorate-General for Health and Food safety (SANTE), Health Emergency Response and Vaccines Unit (03)
European Commission

Jennifer POUGNET

Data Policy Strategy Leader, Personalised Healthcare
Roche

Mario PROHASKY

Principal
IQVIA

Annemien PULLEN

Director Strategy
Veeva MedTech

Thom RASCHE

Partner
Earlybird Venture Capital

Nils REIMERS

Director R&D, Government Affairs and Market Access
Stryker

Simon RICHARDS

VP, Divisional Regulatory Affairs
Abbott Rapid Diagnostics

Nina RIJNDERS

Corporate Partnerships
NLC

Christian-Claus ROTH

Co-President & Global Head Scientific Engagement Governance
IPCAA

Jesus RUEDA RODRIGUEZ

Director General Strategies, Special Projects & International Affairs
MedTech Europe

Lori RUSSELL

Chief Compliance Officer
BioMerieux

Christoph SCHÖBEL

Head of Center for Sleep Medicine, Professor for Sleep- and Telemedicine
University Medicine Essen

Thomas SCHINECKER

CEO
Roche Diagnostics

Françoise SCHLEMMER

Director
Team-NB

Stefan SCHLICHTING

Manager Product & Service Innovation
Unity

Nick SCHNEIDER

Head of Division, New technologies and data use
German Federal Ministry of Health

Peter SCHROEER

VP Regulatory Affairs EMEAC,
Johnson & Johnson Medical Devices

Simon SHELLEY

Global Director of Programme Partnerships
BBC Global News

Alexey SHIRYAEV

Global Clinical Affairs Manager, DNV Product Assurance
President of Team-NB

Stacey SHULMAN

Vice President Internet of Things Group and GM Health
Life Sciences and Emerging Technologies, Intel Corporation

Stuart SILK

President Europe, Latin America, Canada
Stryker

Carlos SISTERNAS

Director, Fenin
Bord member, MedTech Europe

Matt SKLADANY

Director, Operations, IVD Solutions & MedTech CoE
IQVIA

Luc SOLER

Founder and Presiden
Visible Patient

Ilker SOYDAN

CEO
EchoGuide

Julia STECKELER

CEO
MedicalMountains GmbH

Jeff STONADGE

Health Economics & Reimbursement Director
Zimmer Biomet EMEA

Michael STRÜBIN

Director Digital Health
MedTech Europe

Alan SUMNER

Head of Market Access & Public Affairs
Roche Diagnostics UK & Ireland

Karen TAYLOR

Director
Deloitte - UK Centre for Health Solutions

Rob TEN HOEDT

Chairman - MedTech Europe
Executive Vice President and President, EMEA - Medtronic

Eric THEPAUT

EMEA President
Boston Scientific

Laetitia THEVENON

Healthcare Compliance and External Collaboration Manager
ResMed

Luella TRICKETT

Director, Value & Access
Association of British HealthTech Industries (ABHI)

Janet TRUNZO

Senior Advisor to the President and Senior Executive Vice President, Technology and Regulatory Affairs
AdvaMed

Vlada TUSCO

Partnerships Manager
BBC Global News

Félix UEDELHOVEN

Head of Government Affairs and Policy, Europe
GE Healthcare

Meredith VAN DOOREN

Director in Innovation Incentives and IP
Deloitte

Erik VAN RAAIJ

Professor of Purchasing and Supply Management in Healthcare
Erasmus University - Rotterdam School of Management, Netherlands

Stephan VEHMEIJER

Orthopaedic surgeon
Orthoparc, Bosch en Duin, The Netherlands

Yves VERBOVEN

Senior Adviser
MedTech Europe

Pascal VERDONCK

Professor Biomedical Engineering & Medical Technology, Ghent University
Chairman Board of Directors AZ Maria Middelares hospital - Vice chairman Belgian Association of Hospital Directors

Kerstin WAGNER

EVP Global Marketing & Sales Operations
Siemens Healthineers

Pamela WEAGRAFF

Senior Principal
IQVIA MedTech Regulatory Solutions

Errol WEISS

Chief Security Officer
H-Isac

Thomas WEJS MØLLER

Chair
Competent Authorities for Medical Devices (CAMD) Executive Group

Joanna WILLS

Research Manager Northern Europe
GE Healthcare

Petra WILSON

Senior Adviser, FTI Consulting
Managing Director , Health Connect Partners

Stefan WOLF

CEO
The Binding Site

Christian ZERBI

Partner
McKinsey

Catherine is a partner in McKinsey's London office and a leader in McKinsey's Pharmaceutical and Medical Products practice. 

She focuses on delivering large scale digital and analytics enabled transformations. Her recent work includes global, cross business unit, customer experience and go-to-market model transformations. She works closely with clients to build the capabilities and change programmes to enable lasting change and performance improvements. 

Catherine holds an MSc in Economics from the London School of Economics and a BA in Mathematics from the University of Cambridge.

 

Hani Abouhalka is the Company Group Chairman for Johnson & Johnson (J&J) Medical Devices Companies, the world's largest and most comprehensive medical technology business. He is responsible for the company's Medical Device businesses in Europe, Middle East & Africa (EMEA), which includes surgical technology, orthopaedics, cardiovascular and specialty solutions directed at delivering clinical and economic value to healthcare systems.

A purpose-driven and global leader, Hani brings with him an outstanding 20-year record of driving transformational growth across EMEA's developed and emerging markets, building high-performing teams and championing Johnson & Johnson values.

Throughout his career, Hani has held several leadership roles of increasing responsibility across multiple disciplines (business and strategy development, health economics, operations, and management roles), businesses (Medical Devices, Ethicon, Biosurgery, and Cordis) and geographies, from the US to Lebanon and the UAE to the Benelux region and the UK. Before being appointed to his current role in December 2018, Hani served as Vice President, Medical Devices Strategy Development & Global Operations, focused on advancing the process and execution of the global business strategy, improving portfolio value and implementing critical capabilities.

Known for putting the needs of patients first, Hani is passionate about strengthening Johnson & Johnson's footprint in key markets and advancing diverse talent across the enterprise. He is also committed to shaping sustainable solutions that positively impact the health of millions of people.

Hani is the executive sponsor of the Women's Leadership & Inclusion employee resource group in EMEA, which supports the advancement of gender equality at J&J. He also serves as Board Member of the Johnson & Johnson Foundation, a registered charity responsible for managing J&J's Global Community Impact programs and activities across EMEA.

Hani holds a Bachelor's degree in Biology from Arizona State University and a Master's degree in International Business from Thunderbird, The Garvin School of International Management.

 

Greg Ahlberg is Senior Vice President, Core Laboratory Diagnostics, Commercial Operations. He was appoiinted to his role in October 2020.

Prior to assuming his current position, Greg served as Vice President, General Manager Commercial Operations EMEA.

Greg joined Abbott in 1988 in the Financial Professional Development Program. Greg has served this business across varying roles in finance. manufaturing, and commercial operations throughout his Abbott career, contributing to our company's success in the U.S., Latin Amercian and Asia.

Greg earned a B. Sc. in Finance from Indiana University and an M.B.A. from Kellogg School of Management, Northwestern University.

Dr. Bassil Akra is the CEO and co-owner of QUNIQUE GmbH, a medical device and in-vitro diagnostic consultancy company, located in Germany and Switzerland. He spent the last decade as a subject matter expert at the biggest notified body in Europe and represented locally and the globally the notified body association in the various European discussion. Dr. Akra was the Vice President for strategic business development at the Global Medical Health Services of TÜV SÜD Product Service GmbH in Germany. He has long experience in leadership, business management, research, development, quality management and regulatory approval of medical devices, combination devices and ATMP products. Dr. Akra played an essential role during the implementation of the medical device regulation (MDR 2017/745) in Europe and was involved in the drafting of the several European guidance documents (e.g. MEDDEV, MDCG, etc.). He spent the last years of his career at TÜV SÜD training and educating the various stakeholders on the EU Legislations (e.g. MDD/AIMDD, MDR and IVDR) and their impact on the EU healthcare system.

Executive Vice President for Medical Devices Sector ,Saudi FDA August 2018 till present
Chair Asian Harmonization working party (GHWP).
A seasoned management executive and astute medical professional, offering 20+ years of excellence in hospital management, comprehensive regulatory compliance, and medical technology. Proffering expert advice and detailed clinical engineering strategies for high-end projects, including protocol development, study design, regulatory strategy, and submission and study execution strategies.
Recognized for driving medical device sectoral change and innovation  
 
Ali held a Bs degree in Biomedical Engineering and  MBA degree in information technology management. University of Leicester, UK

Björn is a partner in our London office. He works with pharmaceutical and biotech companies, health systems, payors and providers on cancer-related topics. He leads the McKinsey Cancer Center globally and is also a leader in our Pharmaceuticals & Medical Products Practice in Europe. With a PhD and post-doctoral training in molecular oncology, he is a respected peer of both senior executives and research scientists.

Björn's work covers the whole value chain from early discovery strategies through clinical development to commercialization and reimbursement for cancer medicines. In addition, he supports health systems leaders and manufacturers in defining "adequate outcome" approaches to cancer treatment and developing innovative collaborations to serve patients' needs.

 

Dr Charles Alessi is a globally recognized and trusted leader in health care. He brings to HIMSS a wealth of experience, particularly around health systems and the interface between healthcare, social care and the personalization of wellness. He is a physician in London, with more than 35 years of experience in all aspects of clinical practice in the UK National Health Service. Most recently, he served as the Chairman of the National Association of Primary Care, part of the NHS confederation, where he was at the heart of the recent health and social care reforms.
He is also the Senior Advisor to Public Health England, a position leading thought leadership around productive healthy ageing including dementia, targeting risk reduction. Furthermore, he fulfils key roles in PHE around digital interventions, particularly those that involve behavioral change. Other responsibilites include air quality and antibiotic prescribing. He forms part of the World Health Organization (WHO) Expert Panel that is formulating new guidelines around risk reduction in dementia globally and also leads thought leadership around productive healthy aging. He has extensive experience in military medicine, being a past Medical Director and Director of Clinical Governance for the British forces in Germany and was recently appointed to serve on the Reference Committee tasked with renewing military medicine in the United Kingdom.
He holds a variety of international academic positions both in Europe and the Americas and has published widely in the media and journals. He is an Adjunct Research professor in Clinical Neurosciences at the Schulich School of Medicine at the University of Western Ontario, Canada and Visiting Scholar at the Odette School of business in Windsor, Ontario, Canada. He continues to advise major corporations and national governments around health and care reform, particularly where systemic reform and digital interventions are being considered.
 

Anna-Eva Ampelas is Head of Unit for Medical Devices and Health Technology Assessment in Unit B6 in DG SANTE, European Commission. In this capacity, she is managing files on medical devices, including in vitro diagnostic medical devices, and Health Technology Assessments (HTA). She has almost fifteen years of experience working on health policy and legislation in the European Commission and five years in managerial positions in the Commission. Before taking over the Unit on Medical Devices, Anna-Eva was heading units dealing with pharmaceuticals, substances of human origin, tobacco control and global health.  She was Health Counsellor at the Permanent Representation of Sweden 2002-2006 before joining the European Commission. Anna-Eva has a Master of Laws from Uppsala University

Lieven Annemans is Senior Full Professor at the Vrije Universiteit Brussel and at Ghent University, Belgium, and is specialized in the economics of health and wellbeing. He conducts research related to the economics of health promotion, health technology assessment for medicines and medtech solutions, epidemiological models, financial incentives to stimulate integrated care, and the factors that can improve overall well-being. He provides lectures, trainings and advice regarding health economics, Health Technology Assessment and the economics of Wellbeing. He is Past-President of ISPOR (International Society of PharmacoEconomics and Outcomes Research) was advisor to the Belgian Minister of Health, as well as chairman of the Flemish health council. He received twice the Francqui Chair, a Belgian award for academic excellence. He is author or co-author of > 300 papers in peer-reviewed journals and published four books on health economics, among which "health economics for non-economists" (Pelckmans Pro, 2018).

 

Ingrid Baele, a Belgian national, joined Philips Research Laboratories in Eindhoven, The Netherlands in 1987. She has a background in physics from the University of Antwerp, Belgium.
In March 1990, she joined Philips Intellectual Property & Standards (IP&S), a worldwide organization that handles all IP matters for Royal Philips. She served in several roles such as patent attorney, IP Strategy & Portfolio Management, Process & Project Management and Head of IP Operations. She has a broad interest in all types of IP, including IP policy related items.
In September 2020, she joined Deloitte Belgium as Director IP Advisory for expanding IP Services provided by Deloitte.
She is member of the ICC IP Commission since 2002, in which she acts as chair since 2018. She also chaired the ICC IP Roadmap task force for the 2014 and 2017 editions.
 

Paulinka Bandel is a graduate in economics with over 20  years experience in B2B marketing, most recently working in the healthcare industry as Head of Marketing at the medical equipment company Draeger. In this role she is responsible for the Go to Market strategy and the market implementation of new medical device interoperability solutions that Draeger is developing together with partners. Previously, Paulinka was based in Asia where she was responsible for the Marketing department of the Draeger Greater China organisation. Before Paulinka joined Draeger, she was based in the UK heading up the global marketing of the cable assembly company Volex Group plc. A Dutch national, she started her professional career in Marketing Communications at a distributor of IT systems called Landis NV, now Westcon-Comstor, based in the Netherlands.

 

Birgit Bauer, Social Media & Digital Health Expert, Journalist, Speaker and Analyst and Patient Expert

Birgit is German and works with a Business Partner in the company, the Manufaktur für Antworten UG (www.manufaktur-fuer-antworten.de) . Birgit works as Social Media and Digital Health Expert, Journalist and Speaker with a more than 16 years' experience and a specialisation in Healthcare, developing Workshops and Talks about the use of Social Media for Target Groups e.g. Patients, Patient Organisation, NPO, Industry and BioTech Companies, Start-Ups and governmental institutions. In her role as Consultant, she designs and realize Social Media - and Communication Strategies for different Businesses or Patient Projects and brings the Ideas and Strategies into the reality. With a team Birgit also designs and performs Feasibility Studies. 

Birgit aka @Birgitpower on Twitter (https://twitter.com/Birgitpower) is one of the most influential Blogger about Multiple Sclerosis and Healthcare in Germany and Europe. She started her Blog "Fast normal! Mein Leben mit MS" - " Almost normal - My Life with MS" http://leben-arbeiten-mit-multiple-sklerose.blogspot.de/    in 2007. 

Birgit is a so-called Patient Expert and Eupati Fellow. She supports the European Multiple Sclerosis Platform voluntary, is chair of the Patient Advisory Group of the European Society of Radiology, had a mandate from 2017 to 2019 as Co-lead (PCWP = Patient and Consumer Working Party) of the Digital Media & Health Topic Group at the European Medicines Agency, is a member of the Editorial Board of the "Data Saves Lives" Initiative and is involved in different Advisory Boards, Committees and Focus Groups. She is a Co-Author of different scientific Whitepapers and Publications around the theme "Patient - Doctor Communication".

Birgit about Digital Health Solutions: 

"Digital Health Solutions can help people living with chronic conditions in different ways. There are a lot of benefits for patients in the digital world to make lives easier. And we have to find the best ways how to use those tools in a meaningful way."

 

Thierry was appointed Chief Executive Officer of QIAGEN in 2019, having joined the organization in 2015 where he has been leading QIAGEN's growing presence in Molecular Diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare.

He previously worked at bioMérieux for 15 years in roles of increasing responsibility, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region.

A graduate of Sciences Po (Paris), the College of Europe, London School of Economics, and Harvard Business School, Thierry is also a member of French Foreign Trade Advisors.

Mr Bernasconi has 40 years’ experience in the world of pharmaceuticals, medical technology and trade association leadership. He has worked in senior leadership position in companies such as Johnson & Johnson, Schering Plough (now Merck), and Medtronic. He has exercised his leadership in various geographical areas around the world, including, the US, Europe (France, Italy, Belgium, Switzerland), Turkey, the Middle East and Africa.

Throughout his career he has been involved in trade association activities and responsibilities both for the pharmaceutical industry and the MedTech Industry. Prior to become the CEO of Eucomed and EDMA and then MedTech Europe, he had been elected President of APIDIM (The French Association for the Promotion of Innovation in Medical Devices), and Vice President and Treasurer of SNITEM (French Medical Technology Industry Association).

Odile was appointed VP of Sleep & Respiratory Care EMEA Marketing at ResMed in July 2020. Before that, she was VP of Respiratory Care EMEA Marketing for 4 years, where she was responsible for the successful launch of AirView for Ventilation, a breakthrough telemonitoring solution for patients on long term ventilation at home.  Odile is passionate about biomedical technologies, healthcare transformation and digitalisation, and their impact on the management of chronic respiratory diseases. She has more than 20 year’s experience in the medtech industry and holds a Master of Science in Biomedical Technologies from Compiegne University of Technology (UTC).

Peter advises organizations on compliance with federal, state, and international privacy laws. He works with clients to identify privacy risks and develop data management strategies. Peter is considered a leading authority on the application of privacy and data protection laws to pharmaceutical and medical device companies. Peter helps manage the International Pharmaceutical and Medical Device Privacy Consortium (IPMPC) and has authored dozens of IPMPC responses to public consultations on new legislative and regulatory privacy proposals at the US federal and state levels, as well as in Europe and around the globe. Peter’s clients include some of the world’s largest life sciences companies, as well as startup biotech and medical technology companies. He holds CIPP-E and CIPP-US certifications from the International Association of Privacy Professionals (IAPP).

Mark Bloemendaal (CEO) Mark holds a Master's degree in Electrical Engineering (TU Delft) where he specialised in digital signal processing. His business administration skills were developed via an MBA from the British Open University. Eight years ago, he made a professional career switch towards the healthcare industry supported by a (partly) MBA in Healthcare Management at Erasmus University Rotterdam and a (Cum Laude) Minor 'Medicine for Engineers' from Erasmus MC/Leiden MC. In 2019 he received a certificate from Oxford/Said University in the area of Artificial Intelligence and completed several other AI courses. Mark has more than 25 years of experience in translating high-tech concepts into start-up companies or ventures. He is strong in the development of new technical concepts into concrete product-market combinations, forging and managing technical teams and partnerships, attracting financing and opening targeted markets. Connects technology, specialists, commerce, capital and the market. Mark has 3 areas of expertise: technology, strategic & commercial management and change management (healthcare implementation). The market areas in which he has worked are healthcare, security and the chip industry. Mark has co-founded LivAssured and developed NightWatch (an epilepsy detection device) from TRL3 up to CE certification and European market introduction.

Patrick has joined MedTech Europe as of the 1st of September, as Director, EU Research & Innovation Partnership Policies. He will develop, promote, represent and lead the industry in EU Research and Innovation Partnerships or Programmes, working on European projects and interacting with the European Commission in the set-up, follow-up and coordination of European funding(ed) projects and any other similar EU initiatives.
Patrick will particularly lead MedTech Europe activities and representation in critical framework programmes such as Horizon Europe, EIT Health and others.
Patrick managed a significant number of EU collaborative projects, research infrastructures, coordination actions and networks of excellence. His scientific and technical expertise are in nanomedicine, drug delivery, medical imaging and innovative medical technologies.
In his capacity as Director General, will lead the development of key Industry Strategic Initiatives. Patrick's focus will be to drive the three following key strategic initiatives: MedTech Europe Value-Based Health Care deployment, Digital Health expansion and finalising the EU/Medtech industry public-private partnership to support research and innovation in the healthcare industry.
Patrick was educated as an agronomist at the National Agronomic Institute Paris-Grignon,  and as an engineer at ENGREF (École Nationale du Génie Rural des Eaux et des Forêts), together with a specialisation in DEA Nutrition Humaine at the University PARIS VI (France).

Gerhard Bothma is, currently, the Global Director for Health Economics and Governmental Affairs for Mölnlycke Healthcare in Gothenburg, Sweden.
Gerhard Bothma joined Mölnycke in May 2019.  He started his career in Health Economics, Reimbursement and Market Access in South Africa with Johnson & Johnson.  Over the course of 15 years, he held similar positions for Johnson & Johnson and Baxter in The Middle East, Egypt & Turkey and EMEA.
Gerhard Bothma holds an International Masters in Health Economics and Pharmacoeconomics, Post Graduate Diploma in Project Management, B.Sc (Hon) in Enzymology and B.Sc in Biochemistry.

Juliet has been Chief Executive of the Stroke Association since June 2016. The Stroke Association is the UK's leading stroke charity promoting life after stroke. With a turnover of £35m per year and a staff team of 800, the organisation's activities [object Window] from funding stroke research, to providing services to stroke survivors and their families, influencing and campaigning for change, and educating and working to prevent strokes. There are 1.2 million stroke survivors in the UK, yet stroke still remains the fourth single largest cause of death in the UK and second in the world.

Juliet co-chairs the Stroke Delivery Programme Board with NHS England and is a member of the NHS Assembly.  She is a World Stroke Organisation Board member and Fellow.  She was recently awarded the Order of the British Empire Medal (OBE) in the Queen's 2020 New Year's Honours list.

Prior to joining the Stroke Association, Juliet was at Macmillan Cancer Support for 16 years in a range of roles covering strategy, policy, research and HR. From 2011 - 2015 she was Executive Director of Services and Influencing with a staff team of 800 and a budget of £150m.  She oversaw a programme of award-winning innovations and service design across the UK, and secured important government commitments to improve patient experience and post-treatment support through the 2015 Cancer Strategy for England.
 
Prior to Macmillan, Juliet worked at the British Red Cross in strategy and service evaluation, the Community Development Foundation in fundraising, and a political consultancy. She was a trustee of the Long-Term Conditions Alliance and chaired the Cancer Patient Experience Board for University College London Hospital (UCLH) from 2011 - 2014.

Juliet has a degree in Modern Languages in Oxford and a postgraduate diploma in management. She ran the London Marathon for the Stroke Association in April 2019.
 

Natale Bova is Quality Assurance & Regulatory Affairs Director at Werfen, a worldwide leader in in vitro diagnostics (IVD) in the specialties of Hemostasis, Acute Care Diagnostics and Autoimmunity.  He has 25 years of experience in the IVD sector, both in the regulatory area and in the business management with responsibility over EMEA, LATAM and SEA territories.
Natale is the current chairman of IVD Regulatory Forum at Confindustria Dispositivi Medici, the Italian Association of Medical Device Industry. He has also been representing Werfen at Medtech Europe IVD Regulatory Affairs Committee in the past 15 years.

Ralph leads McKinsey Implementation for marketing and sales in Europe, the Middle East, and Africa (EMEA), and our customer-experience (CX) solutions work in EMEA. His deep expertise in commercial transformation and customer experience includes end-to-end change programs from concept to full implementation, CX measurement systems, and CX software. His experience in designing superior customer-loyalty programs spans airlines, car-rental companies, and retail banks. Ralph currently focuses on serving contract-based industries, such as insurance and banking, in conjunction with his work in other industries.

Examples of Ralph's recent client projects include the following:

  • conducting a full customer-experience transformation for a bank, incorporating zero-based customer journey and process redesign, including digitization
  • building the e-commerce business and digital business unit for a fashion company, applying design thinking and agile ways of working (including full implementation)
  • supporting an insurance company to become more customer focused by introducing a customer-experience measurement system, customer journeys for cross-functional collaboration, and implementing improvement actions
  • creating the group digital strategy for an insurance company, including customer-journey digitization, advanced analytics in pricing, and claims management
  • developing new customer loyalty programs for a European retail bank, global car rental company, major global airline, South American retailer, and other clients

 

Mary Devlin Capizzi is a partner at Faegre Drinker Biddle & Reath, LLP in Washington, DC. Clients in the life sciences, consumer goods and technology sectors rely on Mary to help advance their business goals and achieve regulatory compliance. She has helped specific industries as well as cross-industry groups establish special-purpose consortia addressing business challenges. She worked with industry leaders to establish the International Pharmaceutical and Medical Device Privacy Consortium (IPMPC) in 2002. Mary serves as the Co-Chair of the firm’s Health and Life Science Industry Team and is serving her third term on the firm’s Board. She received her B.A. and M.B.A. from the University of Dallas, and her J.D. from Emory University School of Law.  While in university, Mary completed foreign study programs in Spain, France and Italy.

Alexandre Ceccaldi, PhD, is the General Secretary of the European Technology Platform on Nanomedicine (ETPN), the think tank of medical applications of nanotechnologies in Europe, and coordinator of the H2020 NOBEL Project, which acts for the convergence of all emerging medical technologies from nanotechnologies to digital health. In this framework, he will present the Prize ceremony of the HealthTech Award, which will be hosted on April 20th, during the MedTech Forum 2021.

 

Alexandre Ceccaldi holds a PhD in biology from the University Pierre and Marie Curie in Paris, and an engineering degree from Agro ParisTech, with experience in anticancer strategies, industrial management and innovative design. Previously, he has managed INGESTEM, the first French national public consortium entirely dedicated to R&D on induced pluripotent stem cells and their medical applications. Since 2015, he manages the secretariat of the ETPN in Paris, and provides strategic and operational support to a community of more than 150 member organizations of the European nanomedicine ecosystem, in coordination with the Board of Directors of the platform. More recently, he’s been involved in the design and establishment of the HealthTech4EU Alliance, a long lasting platform born from the NOBEL Project, which will unite for the first time seven European Technology Organizations with applications in healthcare.

 

He has a passion for innovation in healthcare, not for the sake of it, but because it can really change the life of millions of patients every year.

 

From the beginning, Karin's career and academic interests have focused on enabling patient access to innovative medicines and technologies. This has been shaped by the desire to learn more about how funding and access for patients is created, and how value to the healthcare system is provided, through healthcare innovation. Karin has over 20 years' pharmaceutical and medical device industry experience. 

Karin holds a Bachelor of Arts in Human Sciences from the University of Oxford, and a Master of Science in International Health Policy, Health Economics and Health Promotion from London School of Economics and Political Science (LSE).  Karin has a strong background in health economic analyses and evidence generation strategies and has led and published a wide range of Health Economic and Outcomes Research studies including economic models, mixed treatment comparisons, observational studies and HTA methodologies. She is a visiting researcher at the LSE.

 

Karin has lived in Italy, Japan, the United Kingdom and is currently living in Belgium with her family.

 

Richard is currently the Head of Market Access & Pricing at Becton Dickinson (BD) EMEA, for the Diabetes Care franchise. He is also vice-chair of the MedTech Europe ‘Evidence & Payers’ Working Group, and a core contributor to the MedTech Europe EU Value based Procurement Working group. Richard is also the co-­Chair of the ISPOR Medical Device Special Interest Group, and the vice-chair of the HTAi Regulatory Interactions and Conditional Coverage group.(patient access agreements). Within these roles,Richard is focused on creating pragmatic, win-win solutions in value based healthcare that align payers, patients and innovators around outcomes based frameworks. Richard currently lives in Switzerland, and graduated from Bocconi University in Italy, with a Masters in Healthcare Managemen tEconomics and Policy (MIHMEP program), and an undergraduate degree in Management Economics and Public Policy from the University of Guelph, Canada in 2002. You can follow Richard on Twitter: @RichardCharter

Salah-Dine has more than 27 years of experience in drug development. He obtained a PhD in Molecular Immunology from the Biozentrum in Basel, Switzerland. Salah-Dine joined the Toxicology Department in 1990 and had increasing responsibilities at Sandoz and then at Novartis. He created the Discovery and Investigative Safety group, which is globally responsible to investigate all drugs side effects from Discovery to Market. From 2008 to 2010 he was Deputy Head of Translational Science in Europe.

From 2010 to 2019, Salah-Dine was leading the Therapeutic Areas in Preclinical Safety. In this role he was responsible to define all regulatory required toxicity studies, to generate all relevant regulatory documents and to ensure efficient health authorities interactions.

Since 2019 Salah-Dine is the Preclinical Safety Therapeutic Area Head for Oncology, being responsible for the entire portfolio safety strategy from target identification to market access.

Salah-Dine is leading a cross-functional global organization operating from Cambridge, East Hanover (USA) and Basle (Switzerland).

In addition, Salah-Dine is responsible for the IMI public-private partnerships at Novartis. He represents Novartis at the EFPIA Science and Innovation Board and is the Chair of the Research & Innovation Strategy Group (RIS). He has been involved in IMI for the last 12 years.

Bernard Colombo joined Roche in 2008 during the integration of Ventana Medical Systems. At Ventana, he had held various positions in Marketing, Sales and Support and, since 2006, assumed central responsibility for developing the company's business in EMEA as Vice President and General Manager of Ventana Medical Systems. From 2008 to 2010, he spearheaded the acceleration and integration of the RTD (Roche Tissue Diagnostics) business for EMEA-LATAM. He was appointed Head of the EMEA Subregion North-West in the Diagnostics Division in 2010, based in Rotkreuz, Switzerland. In addition, since 2008 he has headed the regional Tissue Diagnostics Working Group. In 2017, he was appointed General Manager for Roche Diagnostics France Management Centre, where he was responsible for the French Domestic, Maghreb and French Speaking Sub-Saharan African markets, before assuming his current position as Regional Head Roche Diagnostics EMEA/LATAM in November 2018.
Bernard has extensive experience in the healthcare industry, particularly in Diagnostics, where he has worked for 34 years, having started at Boehringer Mannheim in 1984 and including 10 years at Bayer Diagnostics. He has lived and worked in France and Switzerland, and holds a Master's degree in Biomedical Engineering from Claude Bernard Lyon 1 University in France.

Erica has over 20 years experience in the In Vitro Diagnostic (IVD) medical device and pharmaceutical industries, within Regulatory Affairs and Quality Assurance.  Following a BSc (Hons), PhD (Neurophysiology) and Post-doctoral research, Erica's industrial experience started at GlaxoSmithKline in the regulation of pharmaceuticals. Further she worked in the arena of clinical trials for medicinal products for Quintiles. Erica then moved into the field of IVD medical devices when she became the Regulatory Affairs Manager for Axis-Shield Diagnostics (Alere Toxicology; now Abbott). She then went into performing independent consultancy work and continued working within the IVD and medical device field, as a continued member of British IVD Association, prior to joining BSI.
Erica joined BSI at the beginning of 2014 as a Technical Specialist/Scheme Manager in the IVD medical devices team. She took the position of Global Head of the IVD Medical Device Team aJune 2016, to lead the IVD Technical team. Erica is currently using her experience to transition the Notified Body (NB) to the new EU IVD Regulation, and led the successful designations of BSI UK and BSI NL NBs to the IVDR. She is leading the expansion of the IVD Technical team for the increased demands under the IVDR. She represents the NB group on Team NB/NB-Med.

Remi Corlin is an investor and entrepreneur focused on medical technologies. In parallel to his current CEO role at Hemeo, Remi is also a non executive Director at Adlens UK Ltd, non executive Chairman at Mussler Medical S.A., and international Market consultant at DOASENSE GmbH. Remi has more than 20 years of experience bringing medical technology to global markets with both large public corporations and small private enterprises. 
Remi is a qualified accountant who started his career in auditing and in finance positions with Apple and Silicon Graphics, migrating to the medtech industry in 1998 with Haemonetics

 

First working in the area of food industry within the DG Internal Market and Industrial Affairs, he joined Commissioner Liikanen Cabinet in charge of enterprise and industrial policy and occupied several management position.
From December 2008 until May 2015, he has been Director in DG GROWTH (DG Internal Market, Industry, Entrepreneurship and SMEs), in charge of competitiveness issues and EU internal market legislation for several industrial sectors, including REACH, engineering industries, medical devices, raw materials.
Since March 2021, his main responsibilities in DG GROW cover: construction, standardisation and engineering industries.

 

Ingmar de Gooijer has worked with and in the healthcare industry around the globe since 2000. He is currently Director Public Policy at the health technology company myTomorrows, a role he combines with moderating a few healthcare events each year.

Michel is a partner in Deloitte Risk Advisory leading the regulatory compliance services for the Life Sciences & Healthcare industry.
He is specialised in Digital Compliance, technology quality, regulatory compliance and governance of business and IT.
Throughout his career, he successfully led regulatory transformation programs helping organisations to become compliant with the new regulations and optimise their regulatory functions through innovation, regulatory technologies, strategic risk management and better governance and interaction between regulatory, IT and business functions.

Brigitte is the head of Materialise Medical, a company focused on personalised solutions leveraging 3D printing technologies. She joined Materialise after more than 20 years of experience in Medical Devices with organisations such as Johnson & Johnson (where she had various management roles including VP EMEA of Neurovascular solutions), Acertys (as CEO) and Mediq (as Transformation Officer). She holds an MBA from INSEAD. She is passionate about driving change in Healthcare to make a difference to patients and healthcare systems. 

Pierre Delsaux is Deputy Director General at the European Commission, Directorate General for Health (DG SANTE) since 01/12/2020.  After studying Law at the University of Liège, he obtained his Master of Law at the Northwestern University, Chicago. He was Legal Secretary at the European Court of Justice.  He worked in the private sector before joining the European Commission in 1991.  ?He was appointed Deputy Director General with responsibilities for the Single Market in the EU. On 01/01/2020 he was appointed Deputy Director General at the European Commission Directorate General for Defence Industry and Space.

Celine Deswarte joined Boston Scientific in May 2017 as European Data Protection Officer. She previously worked at the European Commission as a Policy Officer, part of the team in charge of the ePrivacy Directive review. In that role she was also closely following the negotiations on the GDPR.
Celine Deswarte holds a Master II Degree in European Union Law and a Master II Degree in Public Enterprise Law from the University of Paris II Pantheon Assas (France), She is a French qualified lawyer and passed the bar exam in Dec 2005

Emmett Devereux is Director of Government and Regulatory Affairs for Cook Medical in Europe, Middle East and Africa.  Emmett is focused on developing and implementing strategies and policies that raise awareness of patient access to medical technology. Fostering a business environment that is supportive of innovation in healthcare and the advancement of patient care is a core focus for Emmett.

The development and harmonisation of Global, Middle Eastern, European and National legislation in relation to the medical device industry is a priority for Emmett and the wider Government and Regulatory Affairs team.

Emmett joined Cook Medical in 2001 and was an integral part of the leadership team in Limerick. During his time with Cook the company grew to 900 employees and established an extensive range of shared services, including regulatory and quality teams that support the business across EMEA.  Prior to joining Cook, Emmett held positions at Bausch and Lomb, Summit Technologies and Johnson and Johnson.

Emmett represents Cook Medical on the Medtech Europe Regulatory Affairs Committee and the Public Affairs Committee. He is an active member of the Irish Medical Device Association and is past chair of their Regulatory Affairs Committee. Emmett is also an active member of the UK Trade Association and is an active member on both its Regulatory and Public policy committee. He is a past Board member of MECOMED which is the Medtech Association for the Middle East and North Africa. He currently acts as an industry observer on the International Medical Device Regulators Forum (IMDRF) working group and is an advocate for the for global regulatory harmonisation in the field of Medical Device Regulation.

Emmett also has responsibility for the oversight and approach taken by Cook on a number of key EU Trade associations across many of the member states in the EU

He is a past member of GHTF Study group 3; National Standards Association of Ireland (NSAI); and, of TC210 on the revision to ISO13485.

Michael “Mick” Farrell was appointed ResMed’s CEO and has served as a director since March 2013. He joined the company in 2000 and served in a variety of positions.
Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, DowDuPont, and BHP Billiton.
Mick holds a bachelor of engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology, and a Master of Business Administration from the MIT Sloan School of Management.


Larry Ferrere is a member of the leadership team of the IQVIA MedTech center of excellence, serving medical device and diagnostics companies globally. Mr. Ferrere has working in executive leadership positions for leading technology, solutions, consulting, and managed services providers for 40 years, including IQVIA, the leading provider of concept-to-patient solutions, data and analytics, domain expertise, and managed services for medical device and diagnostics, pharmaceutical, biotech, and consumer health companies around the world.

Pat Fogarty is the Vice President, Assistant General Counsel & Director, Civil Justice Policy at the Advanced Medical Technology Association (AdvaMed). AdvaMed advocates globally for the highest ethical standards and patient access to safe, effective and innovative medical technologies that save and improve lives. Prior to joining AdvaMed in 2019, Mr. Fogarty served as Assistant General Counsel and Compliance Officer at the Biotechnology Innovation Organization (BIO), the worlds largest biotech trade association. Mr. Fogarty holds a B.A. from Virginia Tech and a J.D. from the Syracuse University College of Law.  He is admitted to the District of Columbia Bar.

Position - Head of Life Sciences - Chubb International Division
 
With a general passion for science, Alex studied Biochemistry at Nottingham University. He then joined Chubb as an assistant underwriter into the Technology Specialty in 2003, starting first on Technology risks and then moving over to Life Sciences shortly after. Through his 17 years at Chubb, Alex moved through a variety of underwriting roles managing both Life Science and General Insurance portfolios and has also been active in many wider side projects such as underwriting systems delivery, Strategic Advisory Committee and SME Platform development.
 
Alex now has responsibility for all Life Science business for Chubb across 1st and 3rd Party insurance across all reg5 continents outside of North America with responsibilities for technical referral, operational management, systems development, training and delivery of the strategic goals for the Life Science Practice.

Cristiano Franzi joined Baxter in 2017 from Medtronic plc, where he served as vice president and president, Minimally Invasive Therapies Group EMEA from 2015 to 2017. He served as President EMEA at Covidien plc prior to Medtronic's acquisition of Covidien. He served as member of the board of Eucomed Medical Technology from 2013 to 2015.
Cristiano Franzi received a bachelor's degree in marketing from the American University, an MBA from George Washington University and an executive education degree from Harvard Business School.

Morten Frost is Senior Vice President & General Manager at Veracyte.
 
Veracyte is a pioneering genomic diagnostics company with diagnostic tests in 7 out of 10 most prevalent cancers - leverage innovations in genomic technology and machine learning to enable more confident diagnostic, prognostic and treatment decisions.
 
Prior to joining Veracyte Mr. Frost worked at Agilent Technologies in a variety of leadership positions, most recently he served as Head of Global Marketing in the Pathology and Companion Diagnostics business. Mr. Frost held multiple other positions at Agilent Technologies including executive positions in the global sales organization and working with Strategy and Business Development focusing on growth strategies and M&A to expand Agilent’s Diagnostic business. 
 
Prior to Agilent Technologies Mr. Frost worked as a management Consultant at IMS Consulting Group (Now IQVIA) where he advised leading pharmaceutical companies on top-line growth and commercial strategy.
 
Mr. Frost received a MSc in Economics and Business Administration from Copenhagen Business School with complementary executive MBA courses from Stanford University.

 

Miquel-Àngel García is Managing Director and the Head of the Medical Business of Olympus Europa SE & Co. KG. He is responsible for the company's Medical Device businesses in Europe, Middle East & Africa (EMEA). With more than 7.35 million colonoscopies performed annually with Olympus endoscopes in Europe and more than 6,700 patents held in the medical business, Olympus strives permanently for improving the quality of life of patients, as well as reducing the likelihood of readmission and potential healthcare expenses.

With a broad professional experience of more than 20 years, Miquel-Àngel has earned a reputation as an energetic developer and leader for the close partnership with healthcare professionals, specialists and customers. His passion is to drive the digital transformation of Olympus’s medical business in EMEA to optimize customer solutions and make people’s lives healthier, safer and more fulfilling.

Throughout his career, Miquel-Àngel has held several leadership roles of increasing responsibility across multiple disciplines, businesses (Consumer Camera Business, Medical Devices) and geographies. Before being appointed to his current role in April 2019, Miquel-Àngel served as Regional Managing Director South Europe.

Miquel-Àngel holds a Master degree in Business Administration from EAE Business School and a Master degree in Telecommunications Engineering from Universitat Politècnica de Catalunya.

Götz Gerecke is a Managing Director & Senior Partner in Boston Consulting Group's Zurich office. He is BCG's Global MedTech Commercial Sector Leader. 

Götz coordinates BCG's relationship with MedTechEurope and has partnered with us on value-based procurement.

Götz has led numerous commercial model transformation programs. He co-authored BCG's "Milkman Reports" on how to fix the medtech commercial model based a series of global benchmarking studies. The results of the latest study - „Milkman 3.0“ - will be launched at this year‘s MedTech Forum.

Götz holds an MBA from Harvard Business School and a BSc Honors from the European Business School.

Jamie Gramz is head of Digital Applications for Lab Diagnostics at Siemens Healthineers. He has more than 20 years of experience with laboratory automation and healthcare IT solutions and a deep passion for helping laboratories maximize the potential impact and benefit of their workflow solutions.  Jamie holds a BSE in chemical engineering from the University of Pittsburgh, an executive MBA from Washington State University and a certificate in Artificial Intelligence from the MIT Sloan School of Management.  He is married with a family of four kids ages 2-14 and enjoys coaching soccer for his little ones in his spare time.

Associate Director – BCG Platinion (Boston Consulting Group)
 
Axel Griewel is an Associate Director in BCG Platinion’s Cologne office and leads Digital in MedTech in Europe. He delivered several digital transformations in the MedTech industry including digital sales, digital operations and healthcare IT.
 
Axel holds a PhD from the University of Hamburg in Bioinformatics

 

BSc and MSc in Sciences from the University of the Basque Country UPV-EHU, Doctor in Sciences (NeuroScience) from the same university, Masters in Epidemiology from the University of Granada and the Andalusian School of Public Health and Masters in Bioethics from the University Ramon Llul and the Institute Borja of Bioethics. He is the current Director of Innovation of the Basque Foundation for Health Innovation and Research (BIOEF) https://www.bioef.org and the coordinator of Osteba, Basque Office for Health Technology Assessment. Member of the Technical Advisory Group that assesses WHO around HTA and UHC

Anna Hallersten is Head of Regulatory Policy Europe at Roche Diagnostics International.
Anna joined Roche Diagnostics in 2017 in this newly established role to provide strategic counsel and facilitate external advocacy on European regulatory policy issues. Her aspiration is to promote regulatory frameworks that are risk-based, globally convergent and innovation-friendly, leading to patient access to safe and well-performing products.
Prior to this, Anna held positions as Director Public Affairs in SFL and as International Public Policy Manager in F. Hoffmann-La Roche, where she developed and lead implementation of strategic plans for headquarter activity on patient access to medicines in the virology- and autoimmune space.
Anna started her career as a legal officer at the animal disease control division at the Swedish government agency for Agriculture. She gained further experience of EU processes as stagiaire at the European Commission’s DG SANTE and Fleishman Hillard International Communications in Brussels.
Anna holds a Master of Science in Commercial and EU Law from Jönköping International Business School, Sweden. She is based in Basel, Switzerland.

Erik joined the Medical Devices unit of the European Commission in 2012 to kead the implementation of the PIP action plan, followed by negotiations on the new Regulations. Erik is responsible for the operation of several EU working groups (such as MDCG), heads the EU delegation to the multilateral regulatory cooperation in IMDRF, deals with bilateral trade relations and is coordination the cooperation with national competent authorities in the CAMD framework. 
Erik holds a Master defree in law from the University of Uppsala, Sweden, and held various positions in law courts, ministries and agencies in Sweden before joining COM 1997.

 

Meike Hausmann is heading the Olympus HCP/O consulting management department for EMEA within Medical Affairs and taking care of HCP/O interactions as well as transparency reporting.
Meike studied economics and started her career in controlling and joined the EMEA headquarter of Olympus in 2001 where she lead the Controlling for the Medical Business.  5 years ago Meike supported in her new key role the establishment of the new function that is handling topics around compliant healthcare interactions incl. FMV, tiering, contracting, interaction reconciliation and reporting.

Kenny Henderson is a Partner in the Dispute Resolution Team in CMS' London office. He is an experienced litigator who represents sophisticated and blue-chip clients in high stakes disputes, frequently with a multi-jurisdictional element. He is solutions-oriented and deploys litigation strategies tailored to deliver commercial objectives. He has particular expertise in regulated sectors, including pharmaceutical and technology claims.

Kenny is particularly active in the developing area of class and group actions, counselling clients both in defending claims and also on strategies for reducing overall exposure in opt-out and opt-in collective proceedings. He has also acted on many of the highest profile follow-on claims issued in Europe to date. Unusually, he has led matters both on the claimant and the defendant side.

 

Claudia leads digital solutions and has 29-year experience in digital health and partnership with hospitals, healthcare professionals and their ecosystems to drive digital transformation, through deep understanding of needs, capabilities, and skills. She envisions technology and healthcare working as a seamless system to prevent, treat, manage, and even cure disease. A key success factor for the digital health revolution to unlock its potential, is to ensure that it's fully aligned with societal needs and expectations. Working together is paramount to build frameworks that protects people, ensures trust and foster digital innovation.

 

Sabina is Regulatory Strategy Principal at Notified Body TÜV SÜD and acts as representative of TÜV SÜD and Notified Bodies at European level.  She is Chair of NBCG-Med, the EU Commission's working group of Notified Bodies, and Vice-President of Team-NB, the EU Notified Bodies' association.  
Sabina has 20 years of experience as pharmaceutical and medical device regulator and legislator in the Dutch government, serving subsequently in the Medicines Evaluation Board, Ministry of Health and the governmental organization for clinical investigations CCMO.
She has worked as Lead for European Regulation in Philips, where she acted as leader and expert in European Medical Device and Pharmaceutical Regulations on corporate level and was involved in EU MDR/IVDR implementation.
Sabina has a long track record as volunteer in global professional organizations (DIA and RAPS). She is a regular speaker and faculty member in educational conferences on regulatory topics.
She was co-founder and Chair of the RAPS Netherlands Chapter. She is Fellow of RAPS since 2015 and serves in the RAPS Global Board of Directors since 2020.
Sabina holds a PharmD from Leiden University.

 

Mirgen is an international Business Leader working at Johnson and Johnson. Currently he is leading Robotics and Digital Solutions for Europe Middle East and Africa. He has over 12 years of experience in upstream and downstream marketing, new business development, sales, launch of innovative technologies and strategic support to R&D. He holds a master degree in Economics from the University of Bergamo in Italy, has studied International Business in Germany and Marketing in the UK.

Timothy Jinks PhD is the Head of Wellcome Trust's Drug Resistant Infections Priority Program, leading Wellcome's efforts directed at reducing the threat of antimicrobial resistance. In his preceding role he led development of Wellcome's strategic plan to address drug resistant infections. Previously in Wellcome's Innovations Division, he was responsible for a portfolio of over a dozen early stage product development projects covering therapeutics, diagnostics and devices spanning across therapeutic areas such as infectious diseases and oncology. He is a member of the CARB-X Joint Oversight Committee, the Longitude Prize Committee and is Non-Executive Director of Reviral Ltd. Prior to joining the Trust in 2012 he has over a decade of industry experience, most recently as a consultant providing business development, licensing and commercial research services. His scientific background is as a chemist turned molecular biologist having studied at University of Georgia and Princeton University, with academic research experience at Harvard Medical School, Dana Farber Cancer Institute and the MRC National Institute for Medical Research.

 

Phil is an experienced regulatory and quality based professional who has worked in the Medical Device, In-Vitro Diagnostic and Pharmaceutical Industries for over twenty-five years. His core expertise is in the quality and manufacturing requirements for Medical Devices, Diagnostics and Pharmaceuticals.  This has included the writing, implementation and maintenance of Quality systems, auditing of external suppliers and manufacturing/distribution sites and due diligence auditing.
Phil has worked on FDA remediation programs in response to warning letters, consent decrees and import bans; providing strategic consulting to companies. He supported several long-term consulting placements within Medical Device, IVD manufacturing and distribution sites and corporate offices. He supports companies by providing complete business and quality solutions for global market entry requirements, including the setting up of logistics and distribution networks and the license requirements for these operations.

He also has extensive experience in the creation and application of global post market surveillance systems for Complaints Management and Vigilance Reporting. Recent experience has included the development of corporate level post-market surveillance and recall systems and project management of these systems across functional divisions and multiple manufacturing sites. 

Scott Kennedy is senior adviser and Trustee Chair in Chinese Business and Economics at the Center for Strategic and International Studies. His areas of expertise include industrial policy, technology innovation, business lobbying, U.S.-China commercial relations, and global governance. From 2000 to 2014, Kennedy was a professor at Indiana University, where he established the Research Center for Chinese Politics & Business and was the founding academic director of IU's China Office. Kennedy received his Ph.D. in political science from George Washington University, his M.A. in China Studies from the Johns Hopkins University SAIS, and his B.A. from the University of Virginia.

Regina Kloss-Wolf has over 25 years of experience in the In Vitro Diagnostics business environment and currently holds the position of Director Market Access & Strategic Alliances Europe, Africa, Middle East, Turkey & Russia for Abbott Core Diagnostics.

She joined Abbott in 1985 and has held several positions, including Sales, Marketing, Econometrics and Licensing.

During this time Regina served Abbott Core Diagnostics and Abbott Diabetes Care.

She expanded her European market knowledge by accepting a Global Marketing Manager assignment at Abbott HQ, Chicago.  

Before assuming her current role, she functioned as Director, Scientific Leadership Area Europe.

Prior to joining Abbott, Regina Kloss-Wolf was working in the public pharmacy sector in Germany.

 

 

Xenofon Kontargyris joined Olympus in May 2018. He has been specializing on privacy and IT law since 2009. Besides the medtech industry, he has offered privacy counseling in the finance and e-commerce sectors. Xenofon holds a PhD in Law, which he earned from the University of Hamburg by doing research on data protection on the cloud. At Olympus he is a member of the company's Data Protection Office responsible for the EMEA region. He mainly focuses on product privacy and privacy by design topics.

Ewald Kreid is Vice President EMEA for Strategy and Commercial Excellence at Zimmer Biomet, a global leader in musculoskeletal healthcare.

Based in Zug, Switzerland, Ewald oversees organic and inorganic growth strategies and their execution across all of Zimmer Biomet's product segments and countries in Europe, Middle East and Africa. Before joining Zimmer Biomet in 2016, Ewald was a partner at the Boston Consulting Group's healthcare practice.

Ewald is a graduate of the Vienna School of Economics, HEC School of Management and the Kennedy School of Government at Harvard University.

 

Jean-Luc Lemercier has been corporate vice president, EMEA (Europe, Middle East and Africa), Canada and Latin America since July 2017. Prior to assuming his current role, Lemercier served as vice president of transcatheter heart valves EMEA since 2008. Under his leadership at Edwards, the company successfully launched the SAPIEN transcatheter heart valve technology and built its leadership position in Europe. Before joining Edwards, Lemercier served various leadership roles with Johnson & Johnson Cordis from 1996-2008, including leader of the structural heart disease group in the United States; vice president of new business development in Europe; vice president of the European Cordis cardiology division and general manager of Cordis France. Lemercier has more than 30 years of medical device experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States. Lemercier holds a degree as a doctor in pharmacy from the Claude Bernard Lyon 1 University in Lyon, France.

 

Jill Lockett is Managing Director of King’s Health Partners.  Jill leads the King’s Health Partners strategic and operational agenda delivering our 5 year plan, determining and delivering our local and international programmes, maintaining our culture of partnership.  Jill joined King’s Health Partners in 2012, as Director of Performance and Delivery and is a member of the King’s Health Partners Joint Boards, CEOs’ Action Group and AHSC Executive.

Previously, Jill was  Director of the Behavioural and Developmental Psychiatry Clinical Academic Group at the South London and Maudsley NHS Foundation Trust, National Director of Cancer Waits and Heart Team Capital Programme at the Department of Health, Director of Commissioning in a London Primary Care Trust and Chief Executive of a primary care organisation.

Jill is the Chair of Trustees for the Bethlem Museum of the Mind.

 

Appointed within DG RTD as Director for Open Innovation and Open Science in February 2017, he designed, launched and expanded initiatives such as the European Innovation Council (EIC), the VentureEU Initiative, the RDI dimension unde the European Fund for Strategic infrastructures etc.
Since June 2019 he was appointed Director of the EIC Task Force. In charge of the EIC, the EU innovation ecosystems programme as well as R&I related financial instruments (InnovFin, EFSI, InvestEU),  he is also a member of the EFSI Steering Committee, alternate member of the EIF BoDirectors & High Level Representative of the Commission in EUREKA.

Hans Martens was born in Denmark, and he studied Political Science at Aarhus University, specialising in EU affairs and in public administration, and went on to become Associate Professor in international political and economic relations. He joined the European Policy Centre, a leading Brussels think tank, as Chief Executive in 2002, and retired from that post in September 2013. He is now Senior Advisor to EPC and to the Danish think tank Europa. He chairs CHES (Coalition for Health, Ethics and Society), the health policy programme of the EPC. Besides he works as an independent consultant on a number of projects relating to health and energy policies at European level, including on the wider economics of health and care, outcomes measurements, health systems comparisons and evaluation, and public and private healthcare. He is also leading on a project on digitalisation in Europe, including one Health, with the thinktank Europa, building on previous experience on work on the digital Single Market during his years at EPC. Alongside his business career, Hans Martens has been visiting Professor at the Universities of Aarhusand Copenhagen and he is a regular lecturer at Business Schools and Universities in Europe and in the USA, including VCU–Virginia Commonwealth University. He has extensive experience of curriculum design and planning and lectures regularly on the international circuit. He speaks five languages: Danish, English, French, German and Spanish. He is the author of a number of books and articles on Public Administration, European integration, monetary affairs, energy and climate policies and the demographic developments in Europe. Hans Martens is married to Tove Martens, and he lives inSpain, Belgium and Denmark.

David Matusiewicz is Professor of Medical Management at the FOM University - the largest private university in Germany. Since 2015, he has been responsible for the university sector Health & Social Affairs as Dean and as Director of the Research Institute for Health & Social Affairs (ifgs). In addition, he supports technology-driven start-ups in the healthcare sector as a founder or business angel. Matusiewicz is on various advisory boards and an investor in companies that deal with the digital transformation of the healthcare sector. Before taking up his professorship, he worked for several years as a research assistant at Prof. Dr. Jörgen Wasem at Alfried Krupp von Bohlen and Halbach Endowed Chair for Medical Management at the University of Duisburg-Essen.

Amanda Maxwell is European Medtech Regulatory Affairs Editor at Medtech Insight.

 

She has some 30 years’ experience in reporting and providing analysis on developments in the field of medical technology regulatory affairs, with particular focus on the current and future EU regulations for medical devices, IVDs and device/drug combination products. Amanda also has experience in providing medtech regulatory strategy consultancy services, and

is a frequently invited speaker and chair at EU meetings on medtech regulations

 

Ashley McEvoy is Executive Vice President, Worldwide Chair, Medical Devices, Johnson & Johnson. Touching the lives of 278 million patients every year, Ashley oversees the second largest MedTech company in the world. J&J Medical Devices comprises Orthopaedics, Surgery, Cardiovascular, Stroke and Specialty Solutions, and Eye Health businesses.
 
Ashley has been with J&J for more than 20 years and is a passionate people and performance-based leader who has delivered above-market results and champions and advances diversity, equity and inclusion to enable forward-thinking teams who can drive industry change that achieves racial, social and health equity.

With over a decade of experience in venture capital investment, Tamir is responsible for identifying and leading medical device, consumer and health technology investments in line with Johnson & Johnson sector strategies. This includes deal sourcing, due diligence, negotiation, structuring, decision making, execution, and post-investment portfolio management.

Covering Israel and the EU, Tamir is an engaged, hands-on investor who likes to be detail-oriented and involved in his companies. He aims to help young entrepreneurs maximize their potential by providing meaningful advice and empowerment through close relationships and personal commitment to the people and companies in JJDC's portfolio.

Prior to joining JJDC, Tamir worked at GKH Law Offices - one of the largest law firms in Israel, supporting the firm's managing partners for over six years in many aspects of the various deal processes, including marketing and business development.

Tamir has a B.Sc in Chemistry from Tel-Aviv University and an extensive background in biomedical engineering and entrepreneurship, as well as an MBA with a focus on Finance, from the Interdisciplinary Center in Herzliya.

 

Dr Pierre Meulien is Executive Director of the Innovative Medicines Initiative (IMI), a €5 billion PPP. From 2010-2015, Dr Meulien was President and CEO of Genome Canada, where he oversaw the launch of novel projects and networks. From 2007-2010, he was Chief Scientific Officer for Genome British Columbia. From 2002-2007, he served as founding CEO of the Dublin Molecular Medicine Centre. He also worked with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur). He has a PhD in molecular biology from the University of Edinburgh and carried out a post-doctoral fellowship at the Institut Pasteur Paris.

I founded NLC with a mission to bring healttech inventions to market. Due to market complexities and fragmentation, 95% of life-changing, science-based healthtech inventions never reach the patients. At NLC we don't accept this status quo; we scout medical inventions all over Europe and build these out into commercially viable ventures, so that these life-changing inventions can reach the patient.
Throughout the years, we have built a dedicated network, driven by data and learnings. We support our ventures in a variety of different ways, including fund-raising, team-building and legal support. 

Emilia Miloiu coordinates MedTech Europe's activities on Environment and Sustainability. She joined the association in August 2020, bringing a rich experience in health and environment. Over her 11+ years' career, Emilia held various positions within a wide range of organizations, including European health alliances, medical societies, public affairs consultancies, environmental NGO and environmental consulting businesses. Among the organisations, Emilia worked for are the European Chronic Disease Alliance, European Society of Cardiology, European Kidney Health Alliance, Ecorem, Interel and WWF Romania. Her roles were diverse and she acted as a project manager, Secretariat manager, public affairs consultant, association manager and events manager. She has also set up her own consultancy EU Shape Consulting Ltd. and has served several clients in reaching their objectives at European level - to name a few Incisive Health, European Society of Human Reproduction and Embryology and European Pain Federation - EFIC.

Emilia combines a solid scientific background with practical knowledge and hands-on experience of policy and advocacy at European level.  Next to a Master's degree in Public and Private Environmental Management from Freie Universität Berlin, Emilia holds a Bachelor degree in Environmental Physics and a Master's degree in Physics from the West University of Timisoara. A Romanian and Belgian national, she studied in Germany from 2004 to 2008 and worked in Brussels for 8 years. She speaks English and German fluently and has a conversational level of French, besides her native Romanian.

 

Ms Fadzai Munyaradzi is an accomplished sustainability practitioner who leads Medline's corporate social responsibility department in Europe.  In this role, she sets and implements Medline's strategy on ethical sourcing, charitable giving, environmental initiatives and CSR-related communications. Drawing on her first-hand experience with Medline's supply chain due diligence activities and her training as a social compliance auditor*, Ms Munyaradzi has led Medline's engagement with the EU's agenda on mandatory supply chain due diligence and sustainable corporate governance.  

Prior to joining Medline in 2016, Ms Munyaradzi worked at DSM (Netherlands), Germanwatch (Germany), Trialogue (South Africa) and Kaiser Associates EDP (South Africa) in roles spanning greenhouse gas measurement and reporting, climate finance research, corporate social responsibility consulting and economic development consulting.

Ms Munyaradzi holds an MSc Environmental Governance degree from the University of Freiburg in Germany, and a Bachelor of Business Science degree from Rhodes University in South Africa.

*Internal auditor training completed for the WRAP and SA8000 social compliance standards.

 

Michael A. Mussallem was appointed chairman and chief executive officer of Edwards Lifesciences in 2000, when it became an independent, publicly traded company. Under his leadership, Edwards has established its position as a global leader in patient-focused medical innovations with the introduction of lifesaving and life-sustaining therapies such as transcatheter aortic valve replacement, new resilient surgical valves designed for active patients and non-invasive hemodynamic monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives while delivering value to the healthcare system. Mussallem has not only led the development and successful implementation of the company�s patient-focused innovation strategy, but also established Edwards� commitment to philanthropy and corporate social responsibility. Since 2004, the company and Edwards Lifesciences Foundation have gifted almost $90 million to non-profit organizations around the world supporting underserved patients and strengthening communities where its employees live and work. In 2014, Edwards Lifesciences Foundation launched Every Heartbeat Matters, which has impacted more than 1.7 million underserved people and aims to improve the lives of 2.5 million additional underserved structural heart and critical care patients by the end of 2025. During Mussallem�s tenure, Edwards has been recognized among the World�s Most Ethical Companies by the Ethisphere Institute, an organization that defines and advances standards of ethical business practices. In 2019, Edwards was named as one of the Management Top 250 by The Wall Street Journal in partnership with the Drucker Institute, and was also cited as one of the 8 �all stars� achieving high marks in five dimensions of corporate performance. Mussallem has been honored by the Harvard Business Review in its annual Best-Performing CEOs in the World list, including, most recently, in 2019. He has been included in the Forum for Corporate Directors Hall of Fame and received a number of honors including the UC Irvine Medal, a lifetime achievement award from The Phoenix Conference and the Wenger Award for Excellence in Corporate Leadership by WomenHeart. Prior to his current position, Mussallem held a variety of positions at Baxter International from 1979 until 2000, when Edwards was spun off from Baxter. Currently, Mussallem serves on the board of the Advanced Medical Technology Association (AdvaMed) and is an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California. He is a trustee of the University of California, Irvine Foundation and the Rose-Hulman Institute of Technology in Terre Haute, Indiana. Mussallem has served as board chairman of both AdvaMed and the California Healthcare Institute (CHI). He received a bachelor's degree in chemical engineering and an honorary doctorate degree from the Rose-Hulman Institute of Technology.

 

Basir Mustaghni is a Partner & Managing Director in the Frankfurt Office of BCG. He is BCG's Global Leader for Digital Go-To-Market (GTM) in MedTech.
 
Basir's work includes developing and operationalizing Digital GTM strategies for clients across industries, with a strong focus on MedTech. His projects focus mainly on digital & analytics, digital marketing, inside sales, eCommerce, customer success management, eEnabled Sales Force and other digital GTM topics.
 
Basir has studied computer science and business administration at the University of Technology Darmstadt and the Harvard Business School and holds a PhD in finance

Paul NEMITZ is the Principal Advisor in the Directorate General for Justice and Consumers of the European Commission.
He was appointed in April 2017, following a 6-year appointment as Director for Fundamental Rights and Citizen’s Rights in the same Directorate General.
As Director, Nemitz led the reform of Data Protection legislation in the EU, the negotiations of the EU – US Privacy Shield and the negotiations with major US Internet Companies of the EU Code of Conduct against incitement to violence and hate speech on the Internet.
He is a Member of Commission for Media and Internet Policy of the Social Democratic Party of Germany (SPD), Berlin and a visiting Professor of Law at the College of Europe in Bruges. Nemitz is also a Member of the Board of the Verein Gegen Vergessen – Fu?r Demokratie e.V., Berlin and a Trustee of the Leo Baeck Institute, New York. He chairs the Board of Trustees of the Arthur Langerman Foundation, Berlin.
Nemitz studied Law at Hamburg University. He passed the state examinations for the judiciary and for a short time was a teaching assistant for Constitutional Law and the Law of the Sea at Hamburg University.
He obtained a Master of Comparative Law from George Washington University Law School in Washington, D.C., where he was a Fulbright grantee. He also passed the first and second cycle of the Strasbourg Faculty for Comparative Law.
Recent publications: “The Human Imperative – Democracy, Law and Ethics in the Age of Artificial Intelligence”, forthcoming 2021, enhanced translation of “Prinzip Mensch – Demokratie, Recht und Ethik im Zeitalter der Ku?nstlichen Intelligenz, with Matthias Pfeffer, Dietz Verlag, 2020; Critical reflections on Constitutional Democracy in the European Union, S. Garben, I. Govaere and P. Nemitz (Eds.), Oxford, Hart Publishing, 2019.
Follow Paul Nemitz on Twitter: @PaulNemitz . He is the #1 Technology influencer and overall #13 influencer on EU issues in the annual #EUInfluencer Ranking.

Cynthia specialises in Digital Health, including tech transactions, collaborations, data protection, cybersecurity, digital transformation, and smart technologies such as mobile apps, AI, and blockchain.  Her particular focus is direct to patient digital health solutions relating to cardiac, diabetes and diagnostics, including Covid-19.  Cynthia’s data protection practice involves advising on GDPR and worldwide data protection laws, particularly global strategy and compliance, cross border data transfers, big data, analytics, research and commercialisation. Cynthia is a trustee for the Society of Computers & Law, a member of the City of Law Society Data Committee and serves on the MedTech Europe data protection committee.